Diagonal Bio AB (publ) (NGM:DIABIO)

Market Cap	6.54M
Revenue (ttm)	1.39M
Net Income (ttm)	-9.44M
Shares Out	1.63B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,515,100
Average Volume	6,822,641
Open	n/a
Previous Close	0.0040
Day's Range	n/a
52-Week Range	0.0040 - 0.0338
Beta	-1.85
RSI	32.94
Earnings Date	Oct 31, 2025

About Diagonal Bio AB

Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airport...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 5
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DIABIO

Financial Performance

In 2024, Diagonal Bio AB's revenue was 1.13 million, a decrease of -64.30% compared to the previous year's 3.15 million. Losses were -9.93 million, -14.97% less than in 2023.